BioPharmSignal logoBioPharmSignal

Biotech News

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

Lineage Cell Therapeutics (LCTX)Lineage Cell TherapeuticsConference / presentation

Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion

Related news

LCTXLineage Cell Therapeutics2026-03-24 12:00 EST

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

BLTEBelite Bio2026-05-15 12:00 EST

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

IRIXIRIDEX2026-06-09 20:05 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

SGHTSight Sciences2026-03-30 20:05 EST

Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th

HROWHarrow, Inc.2026-05-27 11:00 EST

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

OKYOOKYO Pharma2026-07-27 11:00 EST

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

OKYOOKYO Pharma2026-07-21 13:00 EST

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

BLTEBelite Bio2026-07-15 12:00 EST

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

View all latest news

Lineage Cell Therapeutics

Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic...

Recent company news

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

LCTXLineage Cell Therapeutics2026-07-13 12:00 EST

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

LCTXLineage Cell Therapeutics2026-07-06 12:00 EST

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

LCTXLineage Cell Therapeutics2026-05-12 20:01 EST

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
1.13 USD
Market cap
301.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States